Agenus Inc. (NASDAQ:AGEN) Sees Significant Growth in Short Interest

Agenus Inc. (NASDAQ:AGEN) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 2,800,000 shares, a growth of 5.7% from the August 15th total of 2,650,000 shares. Approximately 13.7% of the shares of the company are short sold. Based on an average daily volume of 724,100 shares, the short-interest ratio is presently 3.9 days.

Agenus Trading Up 2.5 %

Agenus stock opened at $6.23 on Wednesday. Agenus has a 52 week low of $4.41 and a 52 week high of $25.80. The stock has a market cap of $130.82 million, a price-to-earnings ratio of -0.49 and a beta of 1.36. The company’s 50-day moving average price is $7.05 and its two-hundred day moving average price is $10.47.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($2.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.33) by ($1.19). The company had revenue of $23.51 million for the quarter, compared to analyst estimates of $64.73 million. During the same quarter in the previous year, the company earned ($4.00) EPS. Research analysts expect that Agenus will post -10.87 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of AGEN. RPO LLC bought a new position in shares of Agenus during the 4th quarter valued at about $43,000. Point72 DIFC Ltd acquired a new position in Agenus in the second quarter worth approximately $51,000. Ables Iannone Moore & Associates Inc. bought a new position in shares of Agenus in the fourth quarter valued at $65,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Agenus during the 4th quarter valued at $95,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Agenus during the 2nd quarter worth $106,000. Institutional investors own 61.46% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on AGEN. StockNews.com lowered shares of Agenus from a “hold” rating to a “sell” rating in a report on Monday, August 12th. Baird R W cut Agenus from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 19th. Robert W. Baird cut shares of Agenus from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $35.00 to $8.00 in a report on Friday, July 19th. William Blair lowered shares of Agenus from an “outperform” rating to a “market perform” rating in a research note on Thursday, July 18th. Finally, B. Riley cut their price target on Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a report on Wednesday, August 14th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $10.50.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.